Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inmune Bio (INMB) Equity Ratio (2017 - 2025)

Inmune Bio's Equity Ratio history spans 9 years, with the latest figure at 0.76 for Q3 2025.

  • For Q3 2025, Equity Ratio rose 3.83% year-over-year to 0.76; the TTM value through Sep 2025 reached 0.76, up 3.83%, while the annual FY2024 figure was 0.81, 23.85% up from the prior year.
  • Equity Ratio for Q3 2025 was 0.76 at Inmune Bio, down from 0.77 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.96 in Q1 2021 and bottomed at 0.6 in Q1 2024.
  • The 5-year median for Equity Ratio is 0.76 (2022), against an average of 0.76.
  • The largest annual shift saw Equity Ratio dropped 24.3% in 2021 before it soared 30.25% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.8 in 2021, then dropped by 8.46% to 0.73 in 2022, then fell by 10.85% to 0.66 in 2023, then increased by 23.85% to 0.81 in 2024, then dropped by 6.23% to 0.76 in 2025.
  • Per Business Quant, the three most recent readings for INMB's Equity Ratio are 0.76 (Q3 2025), 0.77 (Q2 2025), and 0.78 (Q1 2025).